Answers are grounded in this paper and cite their sources.
• Luspatercept in low-risk MDS-RS patients reduces high suppressive Tregs and mMDSC. • Low mMDSC levels and active CTL response may represent predictive markers for Luspatercept response in MDS-RS patients.
No takes yet. Share an insight, caveat, or question.
Leone et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: